Synonyms: Aloxi® | aurothioglucose | RS-25259-197
palonosetron is an approved drug (FDA (2003), EMA (2009))
Compound class:
Synthetic organic
Comment: Palonosetron is a 'serton' family drug, that is a serotonin 5-HT3 antagonist. Most setrons are antiemetics, apart from alosetron and cilansetron, which are irritable bowel syndrome therapeutics. Setrons are the most widely prescribed antiemetic drugs used in the management of chemotherapy-induced nausea and vomiting (CINV).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: palonosetron |
|
No information available. |
Summary of Clinical Use |
Used to prevent nausea and vomiting caused by highly emetogenic cancer chemotherapy. |
Mechanism Of Action and Pharmacodynamic Effects |
Palonosetron is an antagonist of the serotonin 5-HT3 receptor. Many chemotherapies cause the release of serotonin from the enterochromaffin cells of the small intestine. This neurotransmitter is then able to activate 5-HT3 receptors in the gut and on vagal afferents which activates the vomiting reflex. By inhibiting the activity of endogenous serotonin at these receptors, the drug reduces chemotherapy related nausea and vomiting [1]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |